NHS Framework for the North of England, Branded Medicine
A Contract Award Notice
by THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)
- Source
- Find a Tender
- Type
- Framework (Supply)
- Duration
- 2 year (est.)
- Value
- £169M
- Sector
- HEALTH
- Published
- 01 Mar 2022
- Delivery
- 01 Mar 2022 to 29 Feb 2024 (est.)
- Deadline
- n/a
Concepts
Location
Please refer to Document 3, Schedule 8 in the ITO documents for the list of purchasing points
2 buyers
27 suppliers
- Biogen Maidenhead
- Merck Serono Feltham
- Celltrion Healthcare Slough
- Ul Global Pharma Hertfordshire
- Roche Products Garden City
- Bayer Reading
- Merck Sharpe & Dohme London
- Pfizer Kent
- Accord Devon
- Novo Nordisk Gatwick
- Napp Pharmaceuticals Cambridge
- Eli Lilly Basingstoke
- Ipsen Slough
- Aventis Pharma Reading
- Teva Castleford
- CST Pharma Walsall
- Takeda London
- Gilead Sciences Holborn
- Thornton & Ross Huddersfield
- Janssen Cilag High Wycombe
- Bristol Myers Squibb Uxbridge
- Glaxosmithkline London
- Amgen Cambridge
- Ucb Pharma Slough
- Zentiva Pharma London
- Gedeon Richter Westminster
- Sobi Swedish Orphan Biovitrum Cambridgeshire
Description
HS Framework for the North of England, Branded Medicines – Tranche B, Annual Tranche and Insulin Aspart Biosimilar (Trurapi®)
Lot Division
1 | CM/PHR/20/5600/01 - NHS Framework for the NOFE, Branded Medicines - Tranche B CM/PHR/20/5600/01 - NHS Framework for the North of England, Branded Medicines -Tranche B - 1 March 2022 to 29 February 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months |
2 | CM/PHR/20/5600/02 - NHS Framework for the NOFE, Branded Medicines-Annual Tranche CM/PHR/20/5600/02 - NHS Framework for the North of England, Branded Medicines - Annual Tranche Products. Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months. |
3 | CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi®), South of England - Period of framework: 1 March 2022 to 31 August 2022 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 6 months. |
4 | CM/PHR/20/5600/04-NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London CM/PHR/20/5600/04 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London - Period of framework: 1 March 2022 to 31 August 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 18 months. |
5 | CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), Midlands and East - Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months. |
Award Detail
1 | Biogen (Maidenhead)
|
2 | Merck Serono (Feltham)
|
3 | Celltrion Healthcare (Slough)
|
4 | Ul Global Pharma (Hertfordshire)
|
5 | Roche Products (Garden City)
|
6 | Bayer (Reading)
|
7 | Merck Sharpe & Dohme (London)
|
8 | Pfizer (Kent)
|
9 | Accord (Devon)
|
10 | Novo Nordisk (Gatwick)
|
11 | Napp Pharmaceuticals (Cambridge)
|
12 | Eli Lilly (Basingstoke)
|
13 | Ipsen (Slough)
|
14 | Aventis Pharma (Reading)
|
15 | Teva (Castleford)
|
16 | CST Pharma (Walsall)
|
17 | Takeda (London)
|
18 | Gilead Sciences (Holborn)
|
19 | Thornton & Ross (Huddersfield)
|
20 | Janssen Cilag (High Wycombe)
|
21 | Celltrion Healthcare (Slough)
|
22 | Bristol Myers Squibb (Uxbridge)
|
23 | Glaxosmithkline (London)
|
24 | Roche Products (Garden City)
|
25 | Merck Sharpe & Dohme (London)
|
26 | Pfizer (Kent)
|
27 | Accord (Devon)
|
28 | Napp Pharmaceuticals (Cambridge)
|
29 | Eli Lilly (Basingstoke)
|
30 | Amgen (Cambridge)
|
31 | Aventis Pharma (Reading)
|
32 | Ucb Pharma (Slough)
|
33 | Teva (Castleford)
|
34 | Zentiva Pharma (London)
|
35 | Takeda (London)
|
36 | Gedeon Richter (None)
|
37 | Sobi Swedish Orphan Biovitrum (Cambridgeshire)
|
38 | Aventis Pharma (Reading)
|
39 | Aventis Pharma (Reading)
|
40 | Aventis Pharma (Reading)
|
Award Criteria
PRICE | _ |
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Options are available.
- Award on basis of price.
Reference
- FTS 005550-2022